サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654386

パーキンソン病治療の市場規模、シェア、動向分析レポート：薬剤クラス別、流通チャネル別、地域別、セグメント予測、2025年～2030年

Parkinson's Disease Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
パーキンソン病治療の市場規模、シェア、動向分析レポート：薬剤クラス別、流通チャネル別、地域別、セグメント予測、2025年～2030年
出版日: 2025年01月27日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

パーキンソン病治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のパーキンソン病治療市場規模は、2025～2030年にかけてCAGR 5.04％を記録し、2030年には75億8,000万米ドルに達する見込みです。

これは、PDの新規治療法の研究開発への投資が増加していることに起因しています。2021年8月、パーキンソン財団は、PDの新規治療と治療法の開発を目的とする29の研究プロジェクトに研究助成金として4,300万米ドルを投資すると発表しました。さらに2021年5月、パーキンソン財団はパーキンソン病（PD）に関する研究、ケア、教育プログラムに1,000万米ドルを投資すると発表しました。この投資は、PDに苦しむ人々に無料で認知や遺伝子検査を提供する一助となると考えられます。

このような投資イニシアチブは産業の成長を後押しすると期待されています。過去10年間、PD治療セグメントでは大きな研究開発活動が行われ、革新的なドラッグデリバリー方法の開発につながりました。副作用が少ないため、こうした最先端のドラッグデリバリーシステムは既存のものを凌駕しています。さらに、患者のコンプライアンスが向上したため、こうした手法の配合率が上昇し、産業の拡大に拍車をかけています。さらに、主要製薬会社は、国際市場における疾病治療需要の高まりに対応するため、製品の開発、製造、商業化のための共同研究や提携などの取り組みを行っています。

例えば、2021年11月、STADA ArzneimittelとBioglanは、PD患者の治療に使用される医薬品Lecigon（レボドパ/カルビドパ/エンタカポン）の生産能力を拡大するためにパートナーシップを締結しました。このように、PD患者の治療に使用される医薬品に対する需要の増加は、産業の成長を促進すると予想されます。しかし、神経内科医の数が限られているため、患者の待ち時間が長くなったり、病院での神経外科医の新規採用が困難になるなどの問題が生じています。さらに、現在開業している神経科医の中には、新規のメディケイド患者の受け入れを避ける医師もいるため、他の医師に変更したい患者にとっては困難が生じます。米国神経学会（AAN）の報告書によると、2025年までに神経内科医が約19％不足すると予測されています。

パーキンソン病治療市場レポートハイライト

  • カルビドパ-レボドパ製剤は、振戦、こわばり、徐脈などの症状に対する有効性が長年にわたって確立されていることから、パーキンソン病治療市場を独占し、2024年には25.12%の最大売上シェアを占めました。
  • 小売薬局セグメントは、2024年に41.59％の収益シェアでパーキンソン病治療市場を独占し、患者にとって広く利用しやすく便利であることから、予測期間中に最も速い成長が見込まれます。
  • 北米は、高い有病率、先進的医療インフラ、大規模な研究開発投資などの要因が重なり、2024年の売上高シェア38.03%でパーキンソン病治療市場を独占しました。
  • アジア太平洋のパーキンソン病治療産業は、医療支出の増加、人口の高齢化、神経学的健康に対する消費者の意識の高まりなどを背景に、急速な成長を遂げています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 パーキンソン病治療市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/付随市場の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • パーキンソン病治療市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析

第4章 パーキンソン病治療市場：薬剤クラス別、推定・動向分析

  • セグメントダッシュボード
  • パーキンソン病治療市場：薬剤クラスの変動分析
  • 薬剤クラス別パーキンソン病治療市場
  • 2018～2030年の市場規模と予測と動向分析
  • カルビドパ-レボドパ
  • ドーパミン作動薬
  • MAO-B阻害剤
  • COMT阻害剤
  • 抗コリン薬
  • その他

第5章 パーキンソン病治療市場：流通チャネル別、推定・動向分析

  • セグメントダッシュボード
  • パーキンソン病治療市場：流通チャネルの変動分析
  • 流通チャネル別パーキンソン病治療市場展望
  • 2018～2030年の市場規模と予測と動向分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第6章 パーキンソン病治療市場：地域別、推定・動向分析

  • 地域ダッシュボード
  • 市場規模と予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 市場参入企業の分類
  • 主要市場参入企業による最近の動向と影響分析
  • 企業市場シェア分析、2024年
  • 主要企業プロファイル
    • Cerevel Therapeutics
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Merck &Co., Inc.
    • GlaxoSmithKline plc.（GSK）
    • AbbVie, Inc.
    • H. Lundbeck A/S
    • Amneal Pharmaceuticals LLC
    • Supernus Pharmaceuticals, Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Parkinson's disease treatment market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 6 Global Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 9 North America Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 11 U.S. Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Canada Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 13 Canada Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Mexico Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Mexico Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Europe Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 UK Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 20 UK Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 Germany Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 22 Germany America Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 France Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 24 France Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Spain Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 26 Spain Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Italy Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 28 Italy Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Denmark Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 30 Denmark Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Sweden Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 32 Sweden Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Norway Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 34 Norway Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 China Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 39 China Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Japan Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 41 Japan Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 India Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 43 India Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 South Korea Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 45 South Korea Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Australia Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 47 Australia Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Thailand Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 49 Thailand Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Latin America Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 51 Latin America Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 52 Latin America Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Brazil Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 54 Brazil Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Argentina Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 56 Argentina Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 MEA Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 58 MEA Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 59 MEA Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Africa Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 61 South Africa Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 63 Saudi Arabia Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 UAE Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 65 UAE Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research approaches
  • Fig. 2 Value chain-based sizing & forecasting
  • Fig. 3 Market formulation & validation
  • Fig. 4 Parkinson's disease treatment market segmentation
  • Fig. 5 Market driver analysis (current & future impact)
  • Fig. 6 Market restraint analysis (current & future impact)
  • Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 8 Porter's five forces analysis
  • Fig. 9 Parkinson's disease treatment market: Drug class outlook and key takeaways
  • Fig. 10 Parkinson's disease treatment market: Drug class movement analysis
  • Fig. 11 Carbidopa-Levodopa market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 12 Dopamine Agonist market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 13 MAO-B Inhibitors market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 14 COMT inhibitors market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 15 Anticholinergics market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 16 Others market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 17 Parkinson's disease treatment market: Distribution channel outlook and key takeaways
  • Fig. 18 Parkinson's disease treatment market: Distribution channel movement analysis
  • Fig. 19 Hospital Pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 20 Retail Pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 21 Online Pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 22 North America Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK. Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Italy Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Denmark Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Japan Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 India Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Australia Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Thailand Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 MEA Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Africa Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 UAE Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Kuwait Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 List of key emerging companies/disruptors/innovators
目次
Product Code: GVR-4-68039-990-7

Parkinson's Disease Treatment Market Growth & Trends:

The global parkinson's disease treatment market size is expected to reach USD 7.58 billion by 2030, registering a CAGR of 5.04% from 2025 to 2030, according to a new report by Grand View Research, Inc. This can be attributed to the rising investment in the research and development of novel treatments for PD. In August 2021, the Parkinson's Foundation announced an investment of USD 43 million as a research grant to 29 research projects having the goal of developing novel treatments and therapies for PD. In addition, in May 2021, the Parkinson's Foundation announced an investment of USD 10 million for research, care, and educational programs related to Parkinson's Disease (PD). This investment may aid in providing awareness and genetic testing free of cost to people suffering from PD.

Such investment initiatives are expected to boost industry growth. In the last ten years, there have been significant R&D activities in the PD therapy sector, leading to the development of innovative drug-delivery methods. Due to fewer side effects, these cutting-edge drug delivery systems outperform the existing ones. In addition, the rate of prescription for these techniques has increased due to a rise in patient compliance, which is fueling the expansion of the industry. Moreover, key pharmaceutical companies are undertaking initiatives, such as collaborations and partnerships, for the development, manufacturing & commercialization of products to meet the rising demand for disease treatment in the international market.

For instance, in November 2021, STADA Arzneimittel and Bioglan formed a partnership to expand the production capacity of the medicine Lecigon (levodopa/carbidopa/entacapone) used to treat patients with PD. Thus, increasing demand for medicines that are used to treat patients with PD is anticipated to drive industry growth. However, the limited availability of neurologists leads to issues, such as longer waiting times for patients and difficulty in hiring new neurosurgeons in hospitals. In addition, some of the currently practicing neurologists avoid accepting new Medicaid patients, which creates difficulty for patients who want to switch to another doctor. According to the American Academy of Neurology (AAN) report, around 19% shortage of neurologists is projected by 2025.

Parkinson's Disease Treatment Market Report Highlights:

  • The carbidopa-levodopa segment dominated the Parkinson's disease treatment industry and accounted for the largest revenue share of 25.12% in 2024 due to its long-established efficacy in managing symptoms, particularly tremors, stiffness, and bradykinesia.
  • The retail pharmacy segment dominated the Parkinson's disease treatment market with the revenue share of 41.59% in 2024 and is anticipated to witness the fastest growth over the forecast period due to its widespread accessibility and convenience for patients.
  • North America dominated the Parkinson's disease treatment market with a revenue share of 38.03% in 2024 due to a combination of factors such as a high prevalence of the disease, advanced healthcare infrastructure, and significant research and development investments.
  • The Asia Pacific Parkinson's disease treatment industry is experiencing rapid growth, attributed to rising healthcare expenditure, an aging population, and increased consumer awareness of neurological health.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Distribution Channel
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Parkinson's Disease Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Advancements in treatment options
      • 3.2.1.2. Rising prevalence of Parkinson's disease
      • 3.2.1.3. Increased research and investment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Regulatory and Reimbursement Challenges
  • 3.3. Parkinson's Disease Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Parkinson's Disease Treatment Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Parkinson's Disease Treatment Market: Drug Class Movement Analysis
  • 4.3. Parkinson's Disease Treatment Market by Drug Class (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Carbidopa-Levodopa
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Dopamine Agonists
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. MAO-B Inhibitors
    • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. COMT Inhibitors
    • 4.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Anticholinergics
    • 4.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Parkinson's Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Parkinson's Disease Treatment Market: Distribution Channel Movement Analysis
  • 5.3. Parkinson's Disease Treatment Market by Distribution Channel Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 To 2030 for the following
  • 5.5. Hospital Pharmacy
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Retail Pharmacy
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Online Pharmacy
    • 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Parkinson's Disease Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Key Company Profiles
    • 7.4.1. Cerevel Therapeutics
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Novartis AG
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Teva Pharmaceutical Industries Ltd.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Merck & Co., Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. GlaxoSmithKline plc. (GSK)
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. AbbVie, Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. H. Lundbeck A/S
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Amneal Pharmaceuticals LLC
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Supernus Pharmaceuticals, Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives